DJI45,960.11-1.01%
GDAXI22,612.97-1.50%
GSPC6,477.16-1.74%
HSI24,856.43-1.89%
IXIC21,408.08-2.38%
N22553,603.65-0.27%
AAPL252.89+0.11%
AMZN207.54-1.97%
CL92.65+2.58%
EURUSD1.1535-0.26%
GBPUSD1.3330-0.28%
GC4,388.70-3.59%
GOOG280.74-3.06%
JPM291.66-1.27%
META547.54-7.96%
MSFT365.97-1.37%
NVDA171.24-4.16%
TSLA372.11-3.59%
DJI45,960.11-1.01%
GDAXI22,612.97-1.50%
GSPC6,477.16-1.74%
HSI24,856.43-1.89%
IXIC21,408.08-2.38%
N22553,603.65-0.27%
AAPL252.89+0.11%
AMZN207.54-1.97%
CL92.65+2.58%
EURUSD1.1535-0.26%
GBPUSD1.3330-0.28%
GC4,388.70-3.59%
GOOG280.74-3.06%
JPM291.66-1.27%
META547.54-7.96%
MSFT365.97-1.37%
NVDA171.24-4.16%
TSLA372.11-3.59%
DJI45,960.11-1.01%
GDAXI22,612.97-1.50%
GSPC6,477.16-1.74%
HSI24,856.43-1.89%
IXIC21,408.08-2.38%
N22553,603.65-0.27%
AAPL252.89+0.11%
AMZN207.54-1.97%
CL92.65+2.58%
EURUSD1.1535-0.26%
GBPUSD1.3330-0.28%
GC4,388.70-3.59%
GOOG280.74-3.06%
JPM291.66-1.27%
META547.54-7.96%
MSFT365.97-1.37%
NVDA171.24-4.16%
TSLA372.11-3.59%
CYBERETIKAGLOBAL FINANCIAL INTELLIGENCE
LIVE
USA Seeking Alpha EN

COSCIENS Biopharma Inc. GAAP EPS of -$0.69, revenue of $1.8M

Mar 26, 2026 &03492626202631; 18:49 UTC seekingalpha.com Trending 3/5
Read original on seekingalpha.com ↗
↘
Negative for markets
Sentiment score: -72/100
Moderate impact Short-term (days)
WHAT THIS MEANS
COSCIENS Biopharma reported a significant loss (-$0.69 EPS) with minimal revenue ($1.8M), indicating early-stage biotech struggles. The fresh earnings miss arrives amid broad market weakness (S&P 500 -1.39%, VIX +9.47%), likely amplifying negative sentiment for small-cap biotech.
AI CONFIDENCE
58% Moderate
SENTIMENT GAUGE
NEWS POWER SCORE
AFFECTED ASSETS
↓
COSCIENS
COSCIENSStock
Expected to decline
Large EPS miss (-$0.69) with minimal revenue ($1.8M) signals cash burn and lack of commercial traction; fresh earnings catalyst in risk-off market environment (VIX spike, broad selloff) will likely trigger further downside in small-cap biotech.
↓
S&P 500
^GSPCIndex
Expected to decline
Broad market weakness (-1.39%) and elevated VIX (+9.47%) indicate risk-off sentiment; biotech weakness is symptomatic of sector rotation away from unprofitable growth.
PRICE HISTORY
Loading chart...
⚡ SUGGESTED ACTION
Confidence is moderate (58) due to small-cap illiquidity and lack of historical accuracy data. Consider SHORT or AVOID until market stabilizes; biotech weakness in risk-off environments is predictable but timing is uncertain. Monitor for capitulation or funding announcements. [MOVE:-3.5%]
KEY SIGNALS
Fresh earnings miss (6 min old)Negative EPS with minimal revenueBroad market selloff (S&P -1.39%)VIX spike (+9.47%) = risk-off environmentEarly-stage biotech cash burn signal
SECTORS INVOLVED
BiotechnologyHealthcareSmall-Cap Growth
Analysis generated on Mar 26, 2026 at 18:55 UTC
Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Seeking Alpha. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

RELATED INTELLIGENCE

Laird Superfood GAAP EPS of -$0.16 misses by $0.09, revenue of $13.35M beats by $0.21M
Seeking Alpha Mar 26, 20:18 Negative
Xos GAAP EPS of -$0.86 misses by $0.26, revenue of $5.22M misses by $6.28M
Seeking Alpha Mar 26, 20:15 Negative
Beyond Air CEO Steve Lisi resigns, Robert Goodman appointed successor
Seeking Alpha Mar 26, 20:10 Neutral
CV Sciences Non-GAAP EPS of $0.00, revenue of $13.79M
Seeking Alpha Mar 26, 20:04 Negative
H.B. Fuller outlines $4.55–$4.90 EPS guidance and mid-single digit revenue growth amid supply chain volatility
Seeking Alpha Mar 26, 19:57 Neutral